GLASGOW, Scotland (April 30, 2025)
Dxcover Limited, a clinical-stage diagnostics company pioneering its multiomic spectral analysis (MOSA-Dx™) for early detection of solid tumour cancers, today announced the presentation of real-world data showing, for the first time, a clear and consistent association between increased tumour size and mortality for patients with brain cancer.
Analyses of these findings suggest that diagnosis even one month earlier could reduce the annual risk of mortality by 18-28%, which would be expected to improve survival rates and reduce brain cancer-related healthcare expenditures. Dr Ewan Gray, PhD, Head of Health Economic & Outcomes Data at Dxcover will present the data today at Ca-PRI, which is taking place in Manchester, UK, April 29 and 30. Dr James Cameron, PhD, Clinical Program Manager at Dxcover will present the data today at AACR, which is taking place in Chicago April 25-30.
“Prioritising people with symptoms of a possible brain tumour for urgent brain imaging does matter” said Professor Paul Brennan, Professor of Clinical and Experimental Neurosurgery at the University of Edinburgh and an author on the study. “These new data make it clear that identifying tumours when they are smaller benefits patients, reducing the duration of time in hospital, and increasing survival times. I hope these findings will encourage clinicians and health care organisations to implement strategies to help diagnose brain tumours at the earliest stages, so that appropriate therapy can be initiated as quickly as possible.”
Dxcover’s PANAROMIC™ platform is a differentiated, multiomic technology that reaches beyond tumour DNA to include the complete spectrum of signals from a blood sample that genetic tests miss today. This unique platform combines novel hardware and infrared spectroscopy with AI algorithms to analyse a patient’s blood and detect the presence or absence of disease earlier.
The PANAROMIC™ platform has demonstrated unparalleled sensitivity, using infrared light to vibrate the molecules and produce a spectrum which characterises the whole sample in a way that current tests cannot.
The data presented at Ca-PRI and AACR are from a retrospective cohort study of 1,196 patients in an existing registry database. Key findings from the study include:
- There is a clear and consistent association between tumour size and patient outcomes
- Approximating a 60mm diameter at diagnosis (75th percentile in this patient population) and applying mean growth rate estimates derived by previous studies (1.2% or 2.1% /day), the tumour would be expected to be 31.0mm to 45.5mm 1 month earlier. This would imply an 18-28% decrease in the hazard of brain cancer mortality, which translates to:
- 37-42% rather than 30% of patients surviving at 1 year
- 5-8% rather than 3% of patients achieving long-term (3yr+) survival
- Inpatient bed days would be reduced from approximately 35.1 to 30.6-32.5 days, saving approximately £1300-2200 in healthcare expenditure
- There was a statistically significant reduction in 30-day mortality for patients with glioblastoma multiforme (GBM), an aggressive and rapidly progressing type of brain cancer.
- Further prospective trials or additional RWE should inform our understanding of how earlier diagnosis and intervention impacts outcomes for patients with brain cancer
Commenting on the findings, Cameron Miller, Director of External Affairs and Strategy at The Brain Tumour Charity, said: “There are 130 different types of brain tumours, and treatment can vary depending on where they are situated and on whether the tumour is high grade or low grade, and within those different forms of brain tumours.
“Diagnosing a brain tumour and its status early in the development of the disease is essential for ensuring patients receive timely care that is optimised for their specific tumour type. This Real- World Evidence study is timely, because if we can demonstrate that faster diagnosis will save the NHS money by reducing the number of inpatient bed days, while also potentially reducing mortality, we can build a clear case for investment in new approaches to diagnosis.”
Professor Matthew J. Baker, Co-Founder, CEO and President of Dxcover, said: “The data presented today underscore the potential of our PANAROMIC™ liquid biopsy platform to improve outcomes for patients with brain cancer.”
“The ability to detect tumours earlier can enable the development of novel treatments that would not be feasible with current diagnostic paradigms. Our approach provides a timely and affordable test for the detection of brain cancer earlier, when tumours are smaller, and the data presented today suggest that it could be a game-changer for improving brain cancer outcomes,” Professor Baker added.
Across a variety of cancers, earlier diagnosis means improved survival. Dxcover is developing tests to detect multiple cancers at the earliest stage, when treatment has a better chance to impact outcomes. The company’s patented Drop. Dry. Detect™ method uses much smaller amounts of blood than traditional tests and is non-invasive. This allows high throughput testing and enables detection of cancers that are not readily mapped with traditional approaches. Dxcover has already demonstrated that this method effectively detects brain, colorectal, pancreatic, kidney, ovary, and prostate cancers. The data presented today reinforce the potential of the PANAROMIC™ liquid biopsy in improving brain cancer outcomes.
